AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

American Express

Philip Morris

In a frothy market starved for value, these three dividend stocks combine reasonable valuations with the proven ability to disrupt themselves.

3 Rock-Solid Dividend Stocks You Can Buy and Hold Forever

AstraZeneca PLC (LSE:AZN) has confirmed that the president of its China division has been placed under investigation by local police as part of an anti-corruption drive. Leon Wang, who forms part of its senior executive team, is cooperating with an investigation by Chinese authorities said a statement yesterday from the pharma group released during the Budget speech without giving further details.

AstraZeneca hit again as Chinese president investigated by police

AstraZeneca said on Wednesday the company's China President Leon Wang is currently under investigation and is cooperating with Chinese authorities.

AstraZeneca says its China operations president under investigation

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)-based combinations in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo.

Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca (AZN) closed the most recent trading day at $75.05, moving -1.12% from the previous trading session.

Astrazeneca (AZN) Declines More Than Market: Some Information for Investors

JP Morgan analysts see AstraZeneca PLC (LSE:AZN) in a strong position to dominate the market for a new breast cancer treatment if upcoming clinical trial results are positive. Its drug candidate, camizestrant, or "cami", is undergoing testing in a pivotal phase III trial, named SERENA-6, aimed at treating advanced breast cancer.

AstraZeneca positioned for success in key breast cancer drug trials, says leading US investment bank

Monopar Therapeutics

Monopar Therapeutics Inc. MNPR stock is skyrocketing on Thursday.

Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder

ECC5004/AZD5004 is an investigational oral small molecule GLP-1 receptor agonist licensed to AstraZeneca in November 2023 ECC5004/AZD5004 is an investigational oral small molecule GLP-1 receptor agonist licensed to AstraZeneca in November 2023

Eccogene Receives Milestone Payment of $60 Million from AstraZeneca Following Dosing of the First Patient in Global Phase 2b Program of ECC5004/AZD5004 for the Treatment of Obesity and Type 2 Diabetes

The CHMP recommends approval for AZN's Wainzua for treating polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.

AstraZeneca Receives CHMP's Approval for Wainzua in Europe

AstraZeneca PLC (LSE:AZN) and Ionis Pharmaceuticals' (NASDAQ:IONS) drug Wainzua (eplontersen) has been recommended for approval in the European Union for treating hereditary transthyretin-mediated amyloidosis, a rare disease that damages nerves and leads to disability. The green light is based on a successful phase III trial, showing the drug improved patients' nerve function and quality of life compared to a placebo.

AstraZenca drug for nerve damage given EU Green light

Novo Nordisk

Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Astrazeneca (AZN) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?

AZN or NVO: Which Is the Better Value Stock Right Now?

Astrazeneca (AZN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Astrazeneca (AZN) Loses -5.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Britain's bosses have been given the green light to pay themselves more by their institutional owners Institutional trade body the Investment Association made the call in a new set of guidelines issued today designed to halt a brain drain of top management talent to better-paid jobs in the US. After years of its members hectoring bosses over pay, the IA now says it will introduce principles to enable them to vote through large awards without breaching any guidelines.

UK bosses get green light to hike pay from investment body

AZN inks an agreement with CSPC Pharmaceutical to develop a novel lipid-lowering therapy targeting various cardiovascular diseases.

AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline

Amgen

Investing in the most popular players in the space isn't the only valid approach.

Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks

Bayer AG

Eli Lilly

Pfizer

Sanofi

Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer

SPDR S&P 500 ETF Trust

WestRock

George Soros is among the most renowned and controversial hedge fund managers on the planet.

Like Him Or Hate Him, George Soros Is Betting Big On These 3 Stocks You Should Be Watching

Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.

5 Large Drug Stocks to Watch From a Thriving Industry

AstraZeneca has entered into an exclusive licensing agreement with CSPC Pharmaceutical Group to advance the development of a novel preclinical small molecule lipoprotein(a) (Lp(a)) inhibitor.

AstraZeneca Collaborates with CSPC to Develop Innovative Lp(a) Inhibitor

AstraZeneca PLC (LSE:AZN) shares got a small boost as the UK's largest pharma company snapped up a licence for a drug that could lower in the bloodstream, paying $100 million initially.  The FTSE 100 group struck an exclusive license deal for a pre-clinical novel molecule that has shown it can prevent the formation of types of particles that carry cholesterol in the bloodstream, known as lipoproteins, which are a combination of fat and protein.

AstraZeneca buys licence for cholesterol treatment from China's CSPC

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the BATURA Phase IIIb trial showed AstraZeneca's AIRSUPRA ® (albuterol/budesonide) met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed albuterol.1 The trial included patients with intermittent or mild persistent asthma, including those on short-acting.

AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial

AstraZeneca on Monday said it will pay up to $2 billion to license a cardiovascular drug.

AstraZeneca to pay up to $2 billion to license cardiovascular drug

AstraZeneca said on Monday it would pay up to $1.9 billion to CSPC Pharmaceutical Group Ltd in an exclusive license agreement to boost the Anglo-Swedish drugmaker's cardiovascular pipeline.

AstraZeneca in $1.9 bln licensing deal with HK-listed CSPC

London, UK, 7 October 2024 – Avillion Life Sciences Ltd (“Avillion”) announces that the ongoing BATURA Phase IIIb trial evaluating AstraZeneca's Airsupra (albuterol/budesonide) in patients with intermittent or mild persistent asthma has delivered positive results. The trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction1 in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed albuterol.

Avillion announces positive high-level results from Phase III BATURA trial with AstraZeneca's inhaled anti-inflammatory medication Airsupra in asthma patients

The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in first-quarter 2025.

News for AstraZeneca Stock (AZN)